Search Results
10
Everything
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility
March 26, 2025 02:30 ET
|
ONWARD Medical NV
ONWARD Medical Announces First-in-Human Use of ARC-IM
Lumbar Lead Designed to Restore Standing, Stepping, and
Lower Limb Mobility
Allsup Employment Services Joins United Spinal Association’s Work Readiness Program, Admission Now Open
March 20, 2025 15:02 ET
|
Allsup
Belleville, Illinois, March 20, 2025 (GLOBE NEWSWIRE) -- Allsup Employment Services (AES) is collaborating on another successful Work Readiness & Education Program with United Spinal...
ANEUVO Launches ASPIRE™ Home Study to Evaluate Home Use of ExaStim®
March 19, 2025 09:11 ET
|
ANEUVO
Los Angeles, CA, March 19, 2025 (GLOBE NEWSWIRE) -- ANEUVO, a leader in non-invasive therapy development, has announced the launch of the ASPIRE™ Home Study, the next phase of clinical research for...
TrainHealth Announces FDA Clearance of TrainFES Advanced, Improving Results in Neurological Rehabilitation
March 18, 2025 10:23 ET
|
TrainHealth
TrainHealth seeks to disrupt the neurological rehabilitation market with its new "TrainFES Advanced" device, which they announce has been cleared by FDA.
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
March 14, 2025 16:03 ET
|
NurExone Biologic Inc
ExoPTEN’s Preclinical Study Demonstrates Significant for Enhancing Motor Function, Increasing Blood Flow, and Faster Recovery After Spinal Cord Injuries
Avancée majeure pour EG 427 avec le premier patient traité par EG110A, la première thérapie génique à base d’un vecteur herpétique non réplicatif pour le traitement de la vessie neurogène
February 27, 2025 02:00 ET
|
EG 427
Premier patient traité avec succès dans l’étude clinique EG110A menée dans quatre institutions médicales de premier plan aux États-UnisÉtude de phase 1b/2a visant à recruter 16 patients atteints...
Significant milestone reached for EG 427 with first patient treated with EG110A, first non-replicative herpes vector based genetic medicine for the treatment of neurogenic bladder
February 27, 2025 02:00 ET
|
EG 427
First patient now successfully dosed in the EG110A clinical study being conducted at four leading US institutionsPhase 1b/2a study to recruit 16 patients with neurogenic detrusor overactivity...
ONWARD Medical's ARC-EX System Now Available on US Veterans Affairs Online Procurement Platforms
January 29, 2025 01:30 ET
|
ONWARD Medical NV
ONWARD Medical's ARC-EX System Now Available on US Veterans Affairs Online Procurement Platforms
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 27, 2024 07:01 ET
|
NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 13, 2024 16:14 ET
|
NurExone Biologic Inc
European Medicines Agency Awards Orphan Status to NurExone's ExoPTEN for Spinal Cord Injury, Paving the Way to European Market Entry